DexCom, Inc. DXCM

DexCom, Inc. es una empresa de dispositivos médicos. La empresa se enfoca principalmente en el diseño, desarrollo y comercialización de sistemas de monitoreo continuo de glucosa (CGM, por sus siglas en inglés) para ser utilizados por personas con diabetes y por proveedores de atención médica. Su sistema Dexcom G6 es un sistema CGM que puede ser utilizado como parte de un sistema integrado con otros dispositivos médicos compatibles e interfaces electrónicas, que pueden incluir sistemas automatizados de dosificación de insulina, bombas de insulina, medidores de glucosa en sangre u otros dispositivos electrónicos utilizados para el manejo de la diabetes. Su sistema de monitoreo remoto Dexcom Share, ofrecido para ser utilizado con su sistema Dexcom, utiliza una aplicación en el dispositivo móvil del paciente para transmitir de forma inalámbrica la información de glucosa a la nube y luego a las aplicaciones en los dispositivos móviles de hasta cinco destinatarios designados. Su API en tiempo real de Dexcom permite a desarrolladores de terceros invitados integrar datos de CGM en tiempo real en sus aplicaciones y dispositivos de salud digital. Sus otros productos incluyen Dexcom ONE y Dexcom G7.

DXCM hizo una división de acciones (split) de 4:1 el 13 de junio de 2022: cada acción se convirtió en 4. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 2 oct

  DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

  Dexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.

  

• GlobeNewswire Inc. 1 oct

  ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia

  ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.

  

• Zacks Investment Research 29 sept

  Here's Why DexCom (DXCM) is a Strong Growth Stock

  DexCom (DXCM), a medical device company specializing in continuous glucose monitoring systems, receives a #3 (Hold) rating from Zacks with a VGM Score of B. The company shows strong growth prospects with a Growth Style Score of A and forecasted year-over-year earnings growth of 26.3%. Seven analysts have revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $2.64 per share and an average earnings surprise of +11.4%.

  

• Zacks Investment Research 31 ago

  Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

  A $1,000 investment in DexCom (DXCM) made 10 years ago in August 2016 would be worth $3,981.59 as of August 31, 2026, representing a 298.16% gain. This significantly outperformed the S&P 500's 255.54% gain over the same period. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported 2025 revenues of $4.66 billion (up 16% YoY) and adjusted EPS of $2.09 (up 27.4% YoY). Analysts remain optimistic about future growth despite competitive market pressures.

  

• GlobeNewswire Inc. 14 jul

  Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

  The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.